| Background Acute B-cell lymphoblastic leukemia is the most common hematological malignancy in childhood.Although there are various treatment methods including chemotherapy,targeted therapy,transplantation and so on,which extend the life of patients to a certain extent,there are still a considerable number of patients who die due to relapse or refractory reasons.With the rise of new immunotherapy,the study of immune cells in hematological diseases has attracted the attention of scholars.The immune cells in the microenvironment including myeloid-derived suppressor cells and regulatory T cells,etc.There are many literature reports on blood diseases such as lymphoma,multiple myeloma,and related indicators applied in the clinic to detect the immune status of patients,assess the changes in the disease,and provide a strong basis for the selection of subsequent treatment options.However,there are relatively few studies on myeloid-derived suppressor cells in B-ALL disease.Objective A new method for detecting myeloid-derived myeloid-derived suppressor cells was first proposed,and the changes of peripheral blood MDSCs subtypes before and after chemotherapy in children with B-ALL who were newly diagnosed and scheduled for chemotherapy in our hospital were investigated,and their causes and possible existence were explored.The clinical significance of B-ALL provides new indicators for the treatment of B-ALL and the evaluation of disease status.Methods By reading and analyzing the relevant literature on MDSCs,we know that the characteristic surface markers of myeloid-derived myeloid-derived suppressor cells derived from granulocytes are unclear.This paper first proposes a new idea of using CD10-as the surface marker of G-MDSC,and adopts The specific phenotype of G-MDSC was determined by cytometry as CD14-HLA-DR-CD10-CD33 + CD45 +;In addition,23 children with B-ALL treated in our hospital from December 2018 to December 2019 were selected as the observation group Taking 23 healthy children undergoing physical examination in our hospital as the control group,flow cytometry was used to observe the observation group before chemotherapy and vincristine(VCR),daunorubicin(DNR),and L-aspartate Complete remission after chemotherapy with lasparaginase(L-Asp)and prednisone(PDN)and changes in the proportion of MDSCs subtypes in peripheral blood of the control group(CD14+HLA-DR-CD33+CD45+/CD14+CD33+CD45+,CD14+HLA-DR-CD33+CD45+/CD33+CD45+,CD14-HLA-DR-CD10-CD33+CD45+/CD10-CD33+CD45+,CD14-HLA-DR-CD10-CD33+CD45+/CD33+C D45+).Comparative analysis of MDSCs subtypes before and after treatment in children with B-ALL Differences in type and differences between before and after treatment with healthy controls.Results Compared with normal people,MDSC/CD14+CD33+CD45+,G-MDSC/CD10-CD33+CD45+,G-MDSC/CD33+CD45+increased in peripheral blood of children with B-ALL before chemotherapy,and the difference between the two was statistically significant(P <0.5).The levels of G-MDSC in peripheral blood of children before treatment were higher than those of M-MDSC,and the difference was statistically significant(P <0.05).Comparisons before and after chemotherapy showed that M-MDSC/CD14+CD33+CD45+,M-MDSC/CD33+CD45+,and G-MDSC/ CD10-CD33+CD45+were significantly reduced in children after chemotherapy,and the difference was statistically significant(P <0.5).There was no significant difference in G-MDSC /CD33 + after chemotherapy compared with that before chemotherapy(P> 0.5).Conclusion A new method for the detection of MDSCs may lay the foundation for its clinical application.MDSCs are involved in the occurrence and development of disease and may become a new indicator for evaluating the immune status and progression of disease recurrence in children with B-ALL. |
PDF Full Text Request